Camber Launches Generic Ofirmev®
Piscataway, NJ, July 25, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Acetaminophen Injection to its product line.
Acetaminophen Injection is indicated for:
- Management of mild to moderate pain in adult and pediatric patients 2 years and older
- Management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older
- Reduction of fever in adult and pediatric patients
Acetaminophen Injection is available in 1000mg/100ml (10mg/ml) strength in either 10 or 24 packs of 100 mL single dose vials.
To learn more about Acetaminophen Injection, please visit https://www.camberpharma.com/acetaminophen
Recent articles
- NACDS TSE 2026 Event Recap
- Camber Specialty Marks First Day 1 Injectable Launch
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio






